+

WO1999064405A1 - Efavirenz sous forme cristalline - Google Patents

Efavirenz sous forme cristalline Download PDF

Info

Publication number
WO1999064405A1
WO1999064405A1 PCT/US1999/013199 US9913199W WO9964405A1 WO 1999064405 A1 WO1999064405 A1 WO 1999064405A1 US 9913199 W US9913199 W US 9913199W WO 9964405 A1 WO9964405 A1 WO 9964405A1
Authority
WO
WIPO (PCT)
Prior art keywords
efavirenz
compound
crystalline
crystalline efavirenz
powder diffraction
Prior art date
Application number
PCT/US1999/013199
Other languages
English (en)
Inventor
Lilian A. Radesca
Michael B. Maurin
Shelley R. Rabel
James R. Moore
Original Assignee
Du Pont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22214647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1999064405(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to NZ507713A priority Critical patent/NZ507713A/en
Priority to EEP200000743A priority patent/EE05547B1/xx
Priority to UA2000127048A priority patent/UA74324C2/uk
Priority to JP2000553414A priority patent/JP2002517487A/ja
Priority to SK1818-2000A priority patent/SK18182000A3/sk
Priority to BR9911523-9A priority patent/BR9911523A/pt
Priority to HU0103819A priority patent/HUP0103819A3/hu
Priority to AU44364/99A priority patent/AU758114C/en
Priority to IL139793A priority patent/IL139793A/en
Priority to CA002333550A priority patent/CA2333550A1/fr
Application filed by Du Pont Pharmaceuticals Company filed Critical Du Pont Pharmaceuticals Company
Priority to PL345221A priority patent/PL198504B1/pl
Priority to EP99927468A priority patent/EP1086087A1/fr
Publication of WO1999064405A1 publication Critical patent/WO1999064405A1/fr
Priority to NO20006255A priority patent/NO20006255L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Definitions

  • the potent reverse transcriptase inhibitor Efavirenz is produced in crystalline form. Crystalline Efavirenz exists in several physical forms which are designated Forms 1, 2, 3, 4, and 5 and are characterized by x-ray powder diffraction and differential scanning calorimetry. Pharmaceutical compositions and methods are useful for the treatment of the human immunodeficiency virus (HIV) .
  • HAV human immunodeficiency virus
  • Reverse transcription is a common feature of retrovirus replication. Viral replication requires a virally encoded reverse transcriptase to generate DNA copies of viral sequences by reverse transcription of the viral RNA genome. Reverse transcriptase, therefore, is a clinically relevant target for the chemotherapy of retroviral infections because the inhibition of virally encoded reverse transcriptase would interrupt viral replication.
  • Efavirenz is a compound which is effective in the treatment of the human immunodeficiency virus (HIV) which is the retrovirus that causes progressive destruction of the human immune system with the resultant onset of AIDS.
  • HIV human immunodeficiency virus
  • Effective treatment through inhibition of HIV reverse transcriptase has been shown for both nucleoside based inhibitors, such as azidothymidine, and non-nucleoside based inhibitors.
  • Benzoxazinones such as Efavirenz have been found to be useful non-nucleoside based inhibitors of HIV reverse transcriptase.
  • Efavirenz is known by its chemical name, (S) -6-chloro-4-cyclopropylethynyl-4- trifluoromethyl-1, 4-dihydro-2H-3 , l-benzoxazin-2-one represented in formula (I) :
  • Efavirenz is not only a highly potent reverse transcriptase inhibitor, but is also efficacious against HIV reverse transcriptase resistance. Due to the importance of (S) -6-chloro-4-cyclopropylethynyl-4- trifluoromethyl-1, 4-dihydro-2H-3 , l-benzoxazin-2-one as a reverse transcriptase inhibitor, crystalline forms which exhibit chemical and physical advantages for manufacture, purification and formulation are necessary.
  • Treatment or prevention of the foregoing disorders is accomplished by administering a therapeutically effective amount of Efavirenz to a human or animal subject in need of such treatment or prevention.
  • the treatment with Efavirenz may be accomplished by its use as a single compound, as a pharmaceutical composition ingredient, or in combination with other antivirals, immunomodulators , antibiotics and vaccines.
  • the compound may be administered enterally or parenterally in solid or liquid dosage forms.
  • Efavirenz has not been known previously to exist in stable crystalline polymorphic forms. Accordingly, a need exists for stable crystalline forms of the drug and reliable and reproducible procedures for their manufacture.
  • the present invention is directed to crystalline Efavirenz.
  • a related aspect resides in novel crystalline forms of Efavirenz, designated as Form 1, Form 2, Form 3, Form 4, and Form 5. These forms have been characterized and distinguished from one another by differential scanning calorimetry (DSC) and x-ray powder diffraction analysis.
  • Further aspects of the invention involve pharmaceutical compositions of crystalline Efavirenz and its five forms.
  • the crystalline products of this invention may be formulated into conventional solid pharmaceutical dosage forms or used for the preparation of liquid dosage forms by combining a therapeutically effective amount of the crystalline drug with a pharmaceutically acceptable carrier.
  • the crystalline products may be administered in pharmaceutical compositions which may combine other antivirals, immunomodulators, antibiotics or vaccines.
  • the present invention involves a method for inhibiting reverse transcriptase which comprises administering an amount of crystalline Efavirenz sufficient to result in reverse transcriptase being contacted with an effective inhibitory amount of the active drug substance.
  • the invention involves methods for treating retroviral infections such as human immunodeficiency virus and disorders involving viral replication, which comprise administering a therapeutically effective amount of a pharmaceutical composition comprising the novel crystalline forms of Efavirenz of this invention.
  • Figure 1 shows a powder x-ray diffractogram of the Form 1 crystalline form of (S) -6-chloro-4-cyclopropyl ethynyl-4-trifluoromethyl-1, 4-dihydro-2H-3 , 1-benzoxazin- 2-one.
  • Figure 2 shows a powder x-ray diffractogram of the Form 2 crystalline form of (S) -6-chloro-4-cyclopropyl ethynyl-4-trifluoromethyl-1, 4-dihydro-2H-3 , 1-benzoxazin- 2 -one .
  • Figure 3 shows a powder x-ray diffractogram of the Form 3 crystalline form of (S) -6-chloro-4-cyclopropyl ethynyl-4-trifluoromethyl-1, 4-dihydro-2H-3 , 1-benzoxazin- 2-one.
  • Figure 4 shows a powder x-ray diffractogram of the Form 4 crystalline form of (S) -6-chloro-4-cyclopropyl ethynyl-4-trifluoromethyl-1, 4-dihydro-2H-3 , 1-benzoxazin- 2-one .
  • Figure 5 shows a differential calorimetry thermogram of the Form 1 crystalline form of (S) -6-chloro-4- cyclopropylethynyl-4-trifluoromethyl-1 , 4-dihydro-2H-3 , 1- benzoxazin-2-one.
  • Figure 6 shows a differential calorimetry thermogram of the Form 2 crystalline form of (S) -6-chloro-4- cyclopropylethynyl-4-trifluoromethyl-1, 4-dihydro-2H-3 , 1- benzoxazin-2-one .
  • Figure 7 shows a differential calorimetry thermogram of the Form 3 crystalline form of (S) -6-chloro-4- cyclopropylethynyl-4-trifluoromethyl-1, 4-dihydro-2H-3 , 1- benzoxazin-2-one.
  • Figure 8 shows a differential calorimetry thermogram of the Form 4 crystalline form of (S) -6-chloro-4- cyclopropylethynyl-4-trifluoromethyl-1, 4-dihydro-2H-3 , 1- benzoxazin-2-one .
  • Figure 9 shows a powder x-ray diffractogram of the Form 5 crystalline form of (S) -6-chloro-4-cyclopropyl ethynyl-4-trifluoromethyl-1 , 4-dihydro-2H-3 , 1-benzoxazin- 2 -one .
  • Figure 10 shows a differential calorimetry thermogram of the Form 5 crystalline form of (S)-6- chloro-4-cyclopropylethynyl-4-trifluoromethyl-1 , 4- dihydro-2H-3 , l-benzoxazin-2-one .
  • the present invention provides Form 1 of crystalline Efavirenz.
  • Form 1 crystalline Efavirenz is in substantially pure form.
  • the Form 1 crystalline Efavirenz is characterized by an x-ray powder diffraction pattern comprising four or more 2 ⁇ values selected from the group consisting of 6.0 ⁇ 0.2, 6.3 ⁇ 0.2, 10.3 ⁇ 0.2, 10.8 ⁇ 0.2, 14.1 ⁇ 0.2, 16.8 ⁇ 0.2, 20.0 ⁇ 0.2, 20.5 ⁇ 0.2, 21.1 ⁇ 0.2, and 24.8 ⁇ 0.2.
  • Form 1 crystalline Efavirenz is characterized by an x-ray powder diffraction pattern substantially in accordance with that shown in Figure 1.
  • the Form 1 crystalline Efavirenz is characterized by a differential scanning calorimetry thermogram having a peak at about 138 °C to about 140 °C. In another preferred embodiment, the Form 1 crystalline Efavirenz is characterized by a differential scanning calorimetry thermogram substantially in accordance with that shown in Figure 5.
  • the Form 1 crystalline Efavirenz is characterized by an x-ray powder diffraction pattern comprising four or more 2 ⁇ values selected from the group consisting of: 6.0 ⁇ 0.2, 6.3 ⁇ 0.2, 10.3 ⁇ 0.2, 10.8 ⁇ 0.2, 14.1 ⁇ 0.2, 16.8 ⁇ 0.2, 20.0 ⁇ 0.2, 20.5 ⁇ 0.2, 21.1 ⁇ 0.2, and 24.8 ⁇ 0.2, and further characterized by a differential scanning calorimetry thermogram having a peak at about 138 °C to about 140 °C.
  • the Form 1 crystalline Efavirenz is characterized by an x-ray powder diffraction pattern substantially in accordance with that shown in Figure 1, and is further characterized by a differential scanning calorimetry thermogram having a peak at about 138 °C to about 140 °C.
  • the present invention describes a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of the Form 1 crystalline Efavirenz and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition is contained in a capsule or compressed tablet dosage form, wherein the therapeutically effective amount is about 1 mg to about 1000 mg of Form 1 crystalline Efavirenz .
  • the pharmaceutical composition is contained in a capsule or compressed tablet dosage form, wherein the therapeutically effective amount is about 50 mg to about 200 mg of Form 1 crystalline Efavirenz.
  • the pharmaceutical composition contained in a capsule or compressed tablet contains greater than about 10% by weight of a disintegrant relative to the total dry weight of the dosage form.
  • the pharmaceutical composition is in liquid form.
  • the liquid form comprises about 0.1 percent to about 15 percent by weight of Form 1 crystalline Efavirenz and a liquid vehicle comprising about 50 percent to about 99 percent by weight of polyolesters of medium chain fatty acids.
  • the composition is contained in a soft gelatin capsule, wherein the polyol esters of medium chain fatty acids consist essentially of Cs to Cio fatty acid triglycerides .
  • the liquid form comprising about 0.1 percent to about 15 percent by weight of Form 1 crystalline Efavirenz and a liquid vehicle comprising about 50 percent to about 99 percent by weight of polyolesters of medium chain fatty acids contains a sweetening agent in a range of about 0.1 percent to about 50 percent by weight.
  • the pharmaceutical composition which is in liquid form comprises about 0.1 percent to about 10 percent by weight of Form 1 crystalline Efavirenz and a liquid vehicle about 50 percent to about 99 percent by weight of vegetable oil.
  • the pharmaceutical composition is contained in a soft gelatin capsule, wherein the vegetable oil is soybean oil or peanut oil.
  • the pharmaceutical composition which is in liquid form comprising about 0.1 percent to about 10 percent by weight of Form 1 crystalline Efavirenz and a liquid vehicle about 50 percent to about 99 percent by weight of vegetable oil, contains a sweetening agent in a range of about 1.0 percent to about 50 percent by weight.
  • a capsule or compressed tablet pharmaceutical dosage form comprises : (a) a therapeutically effective amount of Form 1 crystalline Efavirenz;
  • the therapeutically effective amount is about 50 mg to about 200 mg of Form 1 crystalline Efavirenz
  • the surfactant is sodium lauryl sulfate
  • the disintegrant is sodium starch glycolate
  • the binder is lactose
  • the lubricant is magnesium stearate.
  • the present invention describes a method for inhibiting viral replication by a virally encoded reverse transcriptase which comprises providing Form 1 crystalline Efavirenz, in an amount sufficient to result in the HIV reverse transcriptase being contacted with an effective inhibitory amount of the active drug substance.
  • the compound is provided to a human or animal subject to inhibit HIV reverse transcriptase in vivo .
  • the present invention describes a method for the treatment of human immunodeficiency virus infection which comprises administering to a host in need of such treatment a therapeutically effective amount of Form 1 crystalline Efavirenz .
  • the Form 1 crystalline Efavirenz is administered at a dosage from about 1 to about 1000 mg per dose.
  • the Form 1 crystalline Efavirenz is administered at a dosage from about 50 mg to about 200 mg per dose.
  • Form 1 crystalline Efavirenz is prepared by recrystallization of Efavirenz from a hydrocarbon solvent .
  • Form 1 crystalline Efavirenz is prepared by the process comprising:
  • the suitable solvent is heptane or a mixture of tetrahydrofuran and heptane
  • the crystals are isolated by filtration
  • the appropriate temperature is about 70 °C to about 95 °C
  • substantially pure is greater than 90 percent pure.
  • Form 1 crystalline Efavirenz is prepared by heating Form 2, Form 3, Form 4, or Form 5 Efavirenz or mixtures thereof .
  • Form 1 crystalline Efavirenz is prepared by stirring a slurry of Form 2 Efavirenz, Form 3 Efavirenz, or mixtures thereof in a hydrocarbon solvent .
  • the present invention describes Form 2 of crystalline Efavirenz.
  • Form 2 crystalline Efavirenz is in substantially pure form.
  • Form 2 crystalline Efavirenz is characterized by an x-ray powder diffraction pattern comprising four or more 2 ⁇ values selected from the group consisting of: 6.8 ⁇ 0.2, 9.2 ⁇ 0.2, 12.3 ⁇ 0.2, 16.2 ⁇ 0.2, 21.4 ⁇ 0.2, 22.7 ⁇ 0.2, 24.1 ⁇ 0.2, and 28.0 ⁇ 0.2.
  • Form 2 crystalline Efavirenz is characterized by an x-ray powder diffraction pattern substantially in accordance with that shown in Figure 2.
  • Form 2 crystalline Efavirenz is characterized by a differential scanning calorimetry thermogram having a peak at about 116 °C to about 119 °C.
  • Form 2 crystalline Efavirnenz is characterized by a differential scanning calorimetry thermogram substantially in accordance with that shown in Figure 6.
  • Form 2 crystalline Efavirenz is characterized by an x-ray powder diffraction pattern comprising four or more 2 ⁇ values selected from the group consisting of: 6.8 ⁇ 0.2, 9.2 ⁇ 0.2, 12.3 ⁇
  • Form 2 crystalline Efavirenz is characterized by an x-ray powder diffraction pattern substantially in accordance with that shown in Figure 2, and further characterized by a differential scanning calorimetry thermogram having a peak at about 116 °C to about 119 °C.
  • the present invention describes a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of Form 2 crystalline Efavirenz and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition is contained in a capsule or compressed tablet dosage form, wherein the therapeutically effective amount is about 1 mg to about 1000 mg of Form 2 crystalline Efavirenz.
  • the pharmaceutical composition is in liquid form, wherein the therapeutically effective amount is about 0.1 percent to about 15 percent Form 2 crystalline Efavirenz.
  • the present invention describes a method for inhibiting viral replication by a virally encoded reverse transcriptase which comprises providing Form 2 crystalline Efavirenz, in an amount sufficient to result in the HIV reverse transcriptase being contacted with an effective inhibitory amount of the active drug substance.
  • the present invention describes a method for the treatment of viral disorders, such as human immunodeficiency virus and other indications which comprises administering to a host in need of such treatment or prevention a therapeutically effective amount of Form 2 crystalline Efavirenz.
  • the Form 2 crystalline Efavirenz is administered at a dosage from about 1 to about 1000 mg per dose.
  • Form 2 crystalline Efavirenz is prepared by the process of rapid crystallization from a saturated alkane solution of Efavirenz .
  • rapid crystallization comprises : 1) dissolving Efavirenz in a suitable solvent at a suitable temperature to give a saturated solution; 2) filtering the saturated solution; and
  • the suitable solvent is heptane
  • the suitable temperature is about 70 °C to 80 °C
  • cooling the saturated solution rapidly comprises contacting the saturated solution with a cold surface.
  • the present invention describes Form 3 of crystalline Efavirenz in substantially pure form.
  • Form 3 crystalline Efavirenz is characterized by an x-ray powder diffraction pattern comprising four or more 2 ⁇ values selected from the group consisting of: 7.1 ⁇ 0.2, 7.3 ⁇ 0.2, 11.0 ⁇ 0.2, 13.8 ⁇ 0.2, 20.9 ⁇ 0.2, 23.3 ⁇ 0.2, 27.9 ⁇ 0.2, and 33.5 ⁇ 0.2.
  • Form 3 crystalline Efavirenz is characterized by an x-ray powder diffraction pattern substantially in accordance with that shown in Figure 3.
  • Form 3 crystalline Efavirenz is characterized by a differential scanning calorimetry thermogram having a peak at about 108 °C to about 110 °C.
  • Form 3 crystalline Efavirenz is characterized by a differential scanning calorimetry thermogram substantially in accordance with that shown in Figure 7.
  • Form 3 crystalline Efavirenz is characterized by an x-ray powder diffraction pattern comprising four or more 2 ⁇ values selected from the group consisting of: 7.1 ⁇ 0.2, 7.3 ⁇ 0.2, 11.0 ⁇ 0.2, 13.8 ⁇ 0.2, 20.9 ⁇ 0.2, 23.3 ⁇ 0.2, 27.9 ⁇ 0.2, and 33.5 ⁇ 0.2, and further characterized by a differential scanning calorimetry thermogram having a peak at about 108 °C to about 110 °C .
  • Form 3 crystalline Efavirenz is characterized by an x-ray powder diffraction pattern substantially in accordance with that shown in Figure 3, and further characterized by a differential scanning calorimetry thermogram having a peak at about 108 °C to about 110 °C.
  • the present invention describes a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of Form 3 crystalline Efavirenz and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition is contained in a capsule or compressed tablet dosage form, wherein the therapeutically effective amount is about 1 mg to about 1000 mg of Form 3 crystalline Efavirenz.
  • the pharmaceutical composition is in liquid form, wherein the therapeutically effective amount is about 0.1 percent to about 15 percent Form 3 crystalline Efavirenz.
  • the present invention describes a method for inhibiting viral replication by a virally encoded reverse transcriptase which comprises providing Form 3 crystalline Efavirenz, in an amount sufficient to result in the HIV reverse transcriptase being contacted with an effective inhibitory amount of the active drug substance.
  • the present invention describes a method for the treatment of human immunodeficiency virus infection comprises administering to a host in need of such treatment or prevention a therapeutically effective amount of Form 3 crystalline Efavirenz .
  • the Form 3 crystalline Efavirenz is administered at a dosage from about 1 to about 1000 mg per dose.
  • Form 3 crystalline Efavirenz is prepared by the process of stirring a slurry of Form 1 Efavirenz, Form 2 Efavirenz or a mixture thereof, in a hydrocarbon solvent and isolating the crystals.
  • the hydrocarbon is heptane and the crystals are isolated by filtration.
  • the present invention describes Form 4 of crystalline Efavirenz.
  • Form 4 of crystalline Efavirenz is in substantially pure form.
  • Form 4 crystalline Efavirenz is characterized by an x-ray powder diffraction pattern comprising four or more 2 ⁇ values selected from the group consisting of: 3.6 ⁇ 0.2, 6.3 ⁇ 0.2, 9.7 ⁇ 0.2, 11.0 ⁇ 0.2, 12.7 ⁇ 0.2, 13.2 ⁇ 0.2, 16.1 ⁇ 0.2, 19.2 ⁇ 0.2, 19.5 ⁇ 0.2, 20.6 ⁇ 0.2, and 24.3 ⁇ 0.2.
  • Form 4 crystalline Efavirenz is characterized by an x-ray powder diffraction pattern substantially in accordance with that shown in Figure 4.
  • Form 4 crystalline Efavirenz is characterized by a differential scanning calorimetry thermogram having a peak at about 95 °C to about 100 °C.
  • Form 4 crystalline Efavirenz is characterized by a differential scanning calorimetry thermogram substantially in accordance with that shown in Figure 8.
  • Form 4 crystalline Efavirenz is characterized by an x-ray powder diffraction pattern comprising four or more 2 ⁇ values selected from the group consisting of: 3.6 ⁇ 0.2, 6.3 ⁇ 0.2, 9.7 ⁇ 0.2, 11.0 ⁇ 0.2, 12.7 ⁇ 0.2, 13.2 ⁇ 0.2, 16.1 ⁇ 0.2, 19.2 ⁇ 0.2, 19.5 ⁇ 0.2, 20.6 ⁇ 0.2, and 24.3 ⁇ 0.2, and further characterized by a differential scanning calorimetry thermogram having a peak at about 95 °C to about 100 °C.
  • Form 4 crystalline Efavirenz is characterized by an x-ray powder diffraction pattern substantially in accordance with that shown in Figure 4, and is further characterized by a differential scanning calorimetry thermogram having a peak at about 95 °C to about 100 °C.
  • the present invention describes a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of Form 4 crystalline Efavirenz and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition is contained in a capsule or compressed tablet dosage form, wherein the therapeutically effective amount is about 1 mg to about 1000 mg of Form 4 crystalline Efavirenz.
  • the pharmaceutical composition is in liquid form, wherein the therapeutically effective amount is about 0.1 percent to about 15 percent Form 4 crystalline Efavirenz.
  • the present invention describes a method for inhibiting viral replication by a virally encoded reverse transcriptase which comprises providing Form 4 crystalline Efavirenz, in an amount sufficient to result in the HIV reverse transcriptase being contacted with an effective inhibitory amount of the active drug substance.
  • the present invention describes a method for the treatment of human immunodeficiency virus infection which comprises administering to a host in need of such treatment or prevention a therapeutically effective amount of Form 4 crystalline Efavirenz.
  • the Form 4 crystalline Efavirenz is administered at a dosage from about 1 to about 1000 mg per dose.
  • Form 4 crystalline Efavirenz is prepared by recrystallization from a mixed solvent system.
  • Form 4 crystalline Efavirenz is prepared by the process comprising:
  • the suitable solvent is heptane
  • the solution comprises of tetrahydrofuran and Efavirenz
  • the solvent composition is about 1 to about 10 percent tetrahydrofuran in heptane
  • isolating comprises of filtering.
  • the present invention describes Form 5 of crystalline Efavirenz.
  • Form 5 of crystalline Efavirenz is in substantially pure form.
  • Form 5 crystalline Efavirenz is characterized by an x-ray powder diffraction pattern comprising four or more 2 ⁇ values selected from the group consisting of: 10.2 ⁇ 0.2, 11.4 ⁇ 0.2, 11.6 ⁇
  • Efavirenz is characterized by an x-ray powder diffraction pattern substantially in accordance with that shown in Figure 9.
  • Form 5 crystalline Efavirenz is characterized by a differential scanning calorimetry thermogram having a peak at about 108 °C to about 110 °C.
  • Form 5 crystalline Efavirenz is characterized by a differential scanning calorimetry thermogram substantially in accordance with that shown in Figure 10.
  • Form 5 crystalline Efavirenz is characterized by an x-ray powder diffraction pattern comprising four or more 2 ⁇ values selected from the group consisting of: 10.2 ⁇ 0.2, 11.4 ⁇ 0.2, 11.6 ⁇ 0.2, 12.6 ⁇ 0.2, 19.1 ⁇ 0.2, 20.6 ⁇ 0.2, 21.3 ⁇ 0.2, 22.8 ⁇ 0.2, 24.8 ⁇ 0.2, 27.4 ⁇ 0.2, 28.2 ⁇ 0.2, and 31.6 ⁇ 0.2, and further characterized by a differential scanning calorimetry thermogram having a peak at about 108 °C to about 110 °C.
  • Form 5 crystalline Efavirenz is characterized by an x-ray powder diffraction pattern substantially in accordance with that shown in Figure 9, and is further characterized by a differential scanning calorimetry thermogram having a peak at about 108 °C to about 110 °C.
  • the present invention describes a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of Form 5 crystalline Efavirenz and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition is contained in a capsule or compressed tablet dosage form, wherein the therapeutically effective amount is about 1 mg to about 1000 mg of Form 5 crystalline Efavirenz. In another preferred embodiment, the pharmaceutical composition is in liquid form, wherein the therapeutically effective amount is about 0.1 percent to about 15 percent Form 5 crystalline Efavirenz .
  • the present invention describes a method for inhibiting viral replication by a virally encoded reverse transcriptase which comprises providing Form 5 crystalline Efavirenz, in an amount sufficient to result in the HIV reverse transcriptase being contacted with an effective inhibitory amount of the active drug substance.
  • the present invention describes a method for the treatment of human immunodeficiency virus infection which comprises administering to a host in need of such treatment or prevention a therapeutically effective amount of Form 5 crystalline Efavirenz.
  • the Form 5 crystalline Efavirenz is administered at a dosage from about 1 to about 1000 mg per dose.
  • Form 5 crystalline Efavirenz is prepared by recrystallization from a mixed solvent system.
  • the present invention describes a method of treating HIV infection which comprises administering, in combination, to a host in need thereof a therapeutically effective amount of:
  • the present invention describes a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of Form 1, Form 2, Form 3, Form 4, Form 5 or mixtures thereof and a pharmaceutically acceptable carrier.
  • Efavirenz is known by its chemical name, (S)-6- chloro-4-cyclopropylethynyl-4-trifluoromethyl-1, 4- dihydro-2H-3 , l-benzoxazin-2-one represented by formula (I) :
  • the carbinol is oxidized to the benzylic imine, which undergoes an intramolecular cyclization.
  • the benzyl group is removed, and the free amine cyclized to give the active drug substance represented by formula (I) ( Scheme 3 ) .
  • Form 1 is the most thermodynamically stable form. It has a melting point of about 138 °C to about 140 °C, which is the highest of the four forms. Due to its increased stability, it is commonly used for drug formulation. All other forms may be converted into Form 1 during drying at about 60 °C to about 110 °C. Conversion and drying is preferably done in a dryer oven at about 70 °C to about 110 °C under reduced pressure. More preferred is about 75 °C to about 85 °C. Form 5 is converted to Form 1 by heating to 95°C under reduced pressure. Forms 2 and 3 may also be converted into Form 1 using a hydrocarbon slurry at about 65 °C to about 75 °C. Heptane is the most preferred hydrocarbon for this conversion.
  • Form 4 may not convert to Form 1 under these conditions because it is soluble at about 70 °C.
  • Form 1 may be directly crystallized from heptane when the saturated solution is seeded at about 60 °C to about 75 °C and held at about this temperature until Form 1 starts crystallizing.
  • Form 2 may be obtained by rapid crystallization. Rapid crystallization may be accomplished by the filtration of a saturated heptane solution of Efavirenz at about 70 °C to about 80 °C, and crystallization preferably occurs when the solution is contacted with a cooler surface. Form 2 has a melting point of about 116 °C to about 119 °C, observed by differential scanning calorimetry, and as such has exceptional stability. The needles are generally larger than the other forms. Form 2 rejects a variety of impurities common to the process which produces Efavirenz . Form 2 is therefore an important tool for commercial manufacture of Efavirenz concerning purification of second crops, and the recovery of batches which fail drug specifications.
  • Form 2 may be converted into Form 1 by heating in a drier to about 95 °C to 100 °C for about 15 hours.
  • Form 1 may be prepared from Form 2 by slurrying Form 2 in heptane heated to about 70 °C and holding for about 2 hours. The preferred concentration of this slurry is about 12 mL of solvent per gram of Form 2 Efavirenz.
  • Form 2 may also be converted into Form 3 by slurrying in heptane at room temperature for about 8 to about 24 hours.
  • Form 2 may be converted into Form 4 by slurrying
  • Form 2 into heptane to achieve a concentration of about 10 mL solvent per gram of Efavirenz and adding THF to reach a concentration of about 4 to about 6 mL THF in about 100 mL of heptane/THF solution.
  • Form 3 may be obtained by stirring a hydrocarbon slurry of Form 1 or Form 2 at about 25 °C. Heptane is the most preferred hydrocarbon.
  • Form 2 converts faster to Form 3 than Form 1. This conversion takes about 8 hours to about to 24 hours. The conversion of Form 1 to Form 3 takes about a minimum of about 48 hours.
  • Form 3 has a melting point of about 108 °C to about 110 °C, observed by differential scanning calorimetry, and is the most stable form in solution slurries of Efavirenz at room temperature.
  • Form 3 may be converted into Form 1 by drying at about 85 °C to about 90 °C for about 12 to about 24 hours.
  • the conversion of Form 3 to Form 1 may also be accomplished by heating a heptane slurry having a concentration of about 10 mL to 14 mL of solvent per gram of Form 3 Efavirenz to about 65 °C to about 75 °C, and holding the slurry at this temperature for about 2 hours .
  • Form 4 has a melting point of about 95 °C to about 100 °C, observed by differential scanning calorimetry.
  • Form 4 has the most suitable morphology following drying which leads to process advantages related to the handling of the crystalline material. Further, Form 4 possesses a preferred crystal shape, and may therefore be particularly well suited for formulation.
  • the crystals may be obtained from a hydrocarbon slurry of Form 1 or Form 2 when a cyclic ether such as tetrahydrofuran (THF) is added to result in about a 4 to about 6 percent THF to hydrocarbon (v/v) solvent composition.
  • Heptane is the most preferred hydrocarbon. It can be directly crystallized from about a 5 % THF in heptane solution.
  • the solubility of Efavirenz in THF/heptane mixtures is generally high, so in order to maximize yield, certain process protocol is preferably followed.
  • the THF concentration is preferably reduced to about less than 1%, which is accomplished by solvent exchange with heptane.
  • Form 4 has also been obtained by crystallization from a saturated solution in methylcyclohexane. Recrystallization from straight heptane generally results in the formation of Forms 4, 1, 2 or mixtures thereof. Because Form 4 is the form which most commonly results when Efavirenz is crystallized from hydrocarbon/THF mixtures, it is the form which is isolated as a wet cake in the commercial drug manufacture .
  • Form 4 may be converted to Form 1 by drying the crystals at about 80 °C to about 100 °C for about 12 to about 24 hours, preferably in a vacuum dryer.
  • Form 5 has a melting point of about 108°C to about 110°C, observed by differential scanning calorimetry.
  • Form 5 has been determined to be the most thermodynamically stable crystalline form below 40°C.
  • Form 5 is highly crystalline and had the additional property of preferentially excluding impurities which leads to process advantages.
  • the crystals may be obtained by recrystallization from a dilute solution of THF/heptane.
  • the crystals may be obtained from solutions in which either Form 1 or Form 4 have already been isolated.
  • Form 3 Form 1 heptane seeded saturated at 60 to 75 ;C solution
  • THF is intended to mean tetrahydrofuran
  • GC as used herein is intended to mean gas chromatography
  • DMSO is intended to mean dimethylsulfoxide
  • TEDA is intended to mean N,N,N'N' -tetramethylethylenediamine .
  • hydrocarbon refers to alkane solvents. Examples include but are not limited to solvents such as pentane, hexane, heptane, octane, nonane, decane and the like.
  • Preferred mixed solvent systems in the present invention are mixed solvent systems comprising of tetrahydrofuran and hydrocarbons.
  • slurry as used herein is intended to mean a saturated solution of Efavirenz and an additional amount of Efavirenz to give a heterogeneous solution of Efavirenz and a solvent .
  • the present invention describes Form 1 Efavirenz, Form 2 Efavirenz, Form 3 Efavirenz, Form 4 Efavirenz, and Form 5 Efavirenz in substantially pure form.
  • substantially pure means a compound having a purity greater than 90 percent, including 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, and 100 percent.
  • Efavirenz When dissolved, Efavirenz loses its crystalline structure, and is therefore referred to as a solution of Efavirenz. All forms of the present invention, however, may be used for the preparation of liquid formulations in which the drug is dissolved or suspended. In addition, the crystalline Efavirenz may be incorporated into solid formulations .
  • a therapeutically effective amount of the crystalline Efavirenz is combined with a pharmaceutically acceptable carrier to produce the pharmaceutical compositions of this invention.
  • therapeutically effective amount it is meant an amount that, when administered alone or with an additional therapeutic agent, is effective to prevent, suppress or ameliorate the disease or condition or the progression of the disease or condition.
  • the combination of compounds described herein is preferably a synergistic combination.
  • Synergy occurs when the effect (in this case, inhibition of HIV replication) of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent.
  • a synergistic effect is most clearly demonstrated at suboptimal concentrations of the compounds.
  • Synergy can be in terms of lower cytotoxicity, increased antiviral effect, or some other beneficial effect of the combination compared with the individual components .
  • the compounds of the present invention are useful in the inhibition of HIV reverse transcriptase, treatment of infection by human immunodeficiency virus (HIV) and the treatment of consequent pathological conditions such as acquired immunodeficiency syndrome (AIDS) .
  • HIV human immunodeficiency virus
  • AIDS acquired immunodeficiency syndrome
  • Treating AIDS, or treating infection by HIV is defined as including, but not limited to, treatment and prevention of a wide range of states of HIV infection: AIDS, ARC (AIDS related complex) , both symptomatic and asymptomatic, and actual or potential exposure to HIV by blood transfusion, exchange of bodily fluids, bites, accidental needle stick, or exposure to blood during surgery .
  • AIDS AIDS related complex
  • ARC AIDS related complex
  • the compounds of the present invention may be administered orally, parenterally (including subcutaneous injections, intraveneous , intramuscular, intrasternal injection or infusion techniques) , by inhalation spray, rectally, in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable adjuvants and vehicles, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts.
  • Efavirenz described herein may be formulated into pharmaceutical compositions and employed in therapeutic and prophylactic methods as described in US Patent 5,519,021, which is hereby incorporated by reference. These methods include the direction of the forms of the present invention to combinations with one or more agents useful in the treatment of AIDS such as other HIV reverse transcriptase inhibitors, HIV protease inhibitors, antivirals, immunomodulators , antibiotics antiinfectives , or vaccines .
  • HIV reverse transcriptase inhibitor is intended to refer to both nucleoside and non-nucleoside inhibitors of HIV reverse transcriptase (RT) .
  • nucleoside RT inhibitors include, but are not limited to, AZT, ddC, ddl, d4T, and 3TC.
  • non-nucleoside RT inhibitors include, but are no limited to, delavirdine (Pharmacia and Upjohn U90152S) , nevirapine (Boehringer Ingelheim), Ro 18,893
  • HIV protease inhibitor is intended to refer to compounds which inhibit HIV protease .
  • Examples include, but are not limited, saquinavir (Roche, Ro31-8959), ritonavir (Abbott, ABT-538) , indinavir (Merck, MK-639), amprenavir (Vertex/Glaxo Wellcome), nelfinavir (Agouron, AG-1343), palinavir (Boehringer Ingelheim) , BMS-232623 (Bristol-Myers Squibb) , GS3333 (Gilead Sciences) , KNI-413 (Japan Energy) , KNI-272 (Japan Energy), LG-71350 (LG Chemical) , CGP-61755 (Ciba-Geigy) , PD 173606 (Parke Davis) , PD 177298 (Parke Davis) , PD 178390 (Parke Davis), PD 178392 (Parke Davis), U-140690
  • Efavirenz of this invention may be administered in oral dosage forms such as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions.
  • Solid dosage forms (pharmaceutical compositions) suitable for administration may generally contain from about 1 mg to about 1000 mg of crystalline Efavirenz per dosage unit.
  • the crystalline Efavirenz can be combined with a non-toxic, pharmaceutically acceptable inert carrier, such as lactose, starch, sucrose, glucose, methylcellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like.
  • a non-toxic, pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, glucose, methylcellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like.
  • solid dosage forms contain a number of additional ingredients referred to herein as "excipients” .
  • excipients include among others diluents, binders, lubricants, glidants and disintegrants . Coloring agents may also be incorporated.
  • “Diluents” as used herein are agents which impart bulk to the formulation to make a tablet a practical size for compression. Examples of diluents are lactose and cellulose.
  • Binders as used herein, are agents used to impart cohesive qualities to the powered material ensuring the tablet will remain intact after compression, as well as improving the free- flowing qualities of the powder. Examples of typical binders are lactose, starch and various sugars.
  • Lubricants as used herein have several functions including preventing the adhesion of the tablets to the compression equipment and improving the flow of the granulation prior to compression or encapsulation.
  • Lubricants are in most cases hydrophobic materials. Excessive use of lubricants can result in a formulation with reduced disintegration and/or delayed dissolution of the drug substance.
  • Glidants as used herein are substances which improve the flow characteristics of the granulation material. Examples of glidants include talc and colloidal silicon dioxide.
  • Disintegrants as used herein are substances or a mixture of substances added to a formulation to facilitate the breakup or disintegration of the solid dosage form after administration.
  • disintegrants Materials that serve as disintegrants include starches, clays, celluloses, algins, gums and cross-linked polymers.
  • a group of disintegrants referred to as "super- disintegrants” generally are used at a low level in the solid dosage form, typically 1% to 10% by weight relative to the total weight of the dosage unit.
  • Croscarmelose, crospovidone and sodium starch glycolate represent examples of a cross-linked cellulose, a cross-linked polymer and a cross-linked starch, respectively.
  • Sodium starch glycolate swells seven- to twelve-fold in less than 30 seconds effectively disintegrating the granulations that contain it.
  • the disintegrant preferably used in the present invention is selected from the group comprising modified starches, croscarmallose sodium, carboxymethylcellulose calcium and crospovidone.
  • a more preferred disintegrant in the present invention is a modified starch such as sodium starch glycolate.
  • Preferred carriers include capsules or compressed tablets which contain the solid pharmaceutical dosage forms described herein.
  • Preferred capsule or compressed tablet forms generally comprise a therapeutically effective amount of Efavirenz and one or more disintegrants in an amount greater than about 10% by weight relative to the total weight of the contents of the capsule or the total weight of the tablet.
  • Preferred capsule formulations may contain Efavirenz present in an amount from about 5 to about 1000 mg per capsule.
  • Preferred compressed tablet formulations contain Efavirenz in an amount from about 5 mg to about 800 mg per tablet. More preferred formulations contain about 50 to about 200 mg per capsule or compressed tablet.
  • the capsule or compressed tablet pharmaceutical dosage form comprises a therapeutically effective amount of Form 1, 2, 3, or 4 Efavirenz; a surfactant; a disintegrant; a binder; a lubricant; and optionally additional pharmaceutically acceptable excipients such as diluents, glidants and the like; wherein the disintegrant is selected from modified starches; croscarmallose sodium, carboxymethylcellulose calcium and crospovidone.
  • liquid pharmaceutical compositions for oral administration have ranges of the HIV reverse transcriptase inhibitor agents which can vary from about 0.1 to about 15% by weight (wgt) . More preferably, the drug substance component will range from about 1 to about 10% by weight in the composition.
  • the crystalline Efavirenz can be combined with any oral, non- toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
  • the liquid vehicle consists of essentially polyol esters of medium chain fatty acids.
  • polyol esters of medium chain fatty acids is intended to include esters and mixed esters of glycerol, propylene glycol or other open chain polyols such as polyethylene glycol, reacted with medium chain fatty acids, wherein said acid has a chain length between 6 and 12 carbon atoms.
  • Particularly preferred for compositions are triglycerides or diglycerides of the Cs-Cio fatty acids commercially available from the fractionation of coconut oil.
  • Miglyol and “Captex 300” which are described as having a typical composition of about 68% Cs fatty acid (caprylic) triglyceride and about 28% C ⁇ o fatty acid (capric) triglyceride with minor levels of e and C 14 fatty acid triglycerides .
  • the medium chain fatty acid ester component when present serves as the solvent vehicle for the active agent in formulating the compositions of the invention and is present in the composition in the range from about 50% to about 99%, by weight, but more preferably from 70% to 99% by weight.
  • the liquid composition containing polyol esters will contain a sweetening agent which is useful in reducing the oily taste of the medium chain fatty acid ester and thus contributes in a significant way in making the compositions more palatable.
  • the sweetening agent can be selected from a sugar such as sucrose, mannitol, sorbitol, xylitol, lactose, etc. or a sugar substitute such as cyclamate, saccaharin, aspartame, etc. If sugar substitutes are selected as the sweetening agent the amount employed in the compositions of the invention will be substantially less than if sugars are employed. Taking this into account, the sweetening agent can be used in the composition in the range of from 0.1 to 50% by weight and more preferably in the range of 0.5 to 30% by weight.
  • the more preferred sweetening agents are the sugars and particularly sucrose.
  • the particle size of the powdered sucrose used has been found to have a significant influence in the physical appearance of the finished composition and its ultimate acceptance for taste.
  • the preferred particle size of the sucrose component when used is in the range of from 200 to less than 325 mesh US Standard Screen.
  • Efavirenz is combined with a liquid vehicle which is a vegetable oil selected from the class consisting of olive oil, peanut oil, soybean oil, corn oil, safflower oil, sunflower oil, canola oil, or walnut oil.
  • a vegetable oil selected from the class consisting of olive oil, peanut oil, soybean oil, corn oil, safflower oil, sunflower oil, canola oil, or walnut oil.
  • the vegetable oil component serves as the solvent vehicle for the active agent in formulating the compositions of the invention and is present in the composition in the range from 50 to 99%, by weight more preferably from 70% to 99% by weight.
  • the pharmaceutical compositions containing vegetable oil will also contain a sweetening agent which is useful in reducing the oily taste of the vegetable oil and thus contributes in a significant way in making the compositions more palatable.
  • a sweetening agent which is useful in reducing the oily taste of the vegetable oil and thus contributes in a significant way in making the compositions more palatable.
  • the liquid compositions may also contain other components routinely utilized in formulating pharmaceutical compositions.
  • One example of such components is lecithin. Its use in compositions of the invention as an emulsifying agent in the range of from 0.05 to 1% by weight, more preferably from 0.1 to 0.5% by weight may possibly serve to improve absorption of the active drug agent.
  • Other examples of components that may be used are antimicrobial preservatives, such as benzoic acid or parabens; suspending agents, such as colloidal silicon dioxide; antioxidants; topical oral anesthetics ; flavoring agents; and colorants. The selection of such optional components and their level of use in the compositions of the invention is within the level of skill in the art and will be even better appreciated from the working examples provided hereinafter .
  • Crystalline Efavirenz may also be coupled with soluble polymers as targetable drug carriers.
  • soluble polymers can include polyvinylpyrrolidine pyran copolymer, polyhydroxypropylmethacrylamide-phenol , polyhydroxyethyl- aspartamidephenol or polyethylene oxide-polylysine substituted with palmitolyl residues.
  • the crystalline Efavirenz may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels .
  • biodegradable polymers useful in achieving controlled release of a drug
  • a drug for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels .
  • Gelatin capsules of crystalline Efavirenz contain Efavirenz and the liquid or solid compositions described herein. Gelatin capsules may also contain powdered carriers such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours . Tablets can be sugar coated or film coated to mask any unpleasant taste and to protect the tablet from the atmosphere or enteric coated for selective disintegration in the gastrointestinal track.
  • powdered carriers such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours . Tablets can be sugar coated or film coated to mask any unpleasant taste and to protect the tablet from the atmosphere or enteric coated for selective dis
  • water, a suitable oil, saline, aqueous dextrose (glucose) , and related sugar solutions and glycols, such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions .
  • Solutions for parenteral solutions are prepared by dissolving the crystalline Efavirenz in the carrier and, if necessary, adding buffering substances.
  • Anti- oxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid either alone or combined, are suitable stabilizing agents.
  • Citric acid and its salts and sodium EDTA may also be employed.
  • Parenteral solutions may also contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol .
  • Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Co., a standard reference text in this field.
  • Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows: Capsule
  • a large number of unit capsules can be prepared by filling standard two-piece hard gelatin capsules each with 100 mg of powdered active ingredient, 150 mg of lactose, 50 mg of cellulose, and 6 mg magnesium stearic.
  • a mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil can be prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules should then be washed and dried.
  • a digestible oil such as soybean oil, cottonseed oil or olive oil
  • a large number of tablets can be prepared by conventional procedures so that the dosage unit is 100 mg of active ingredient, 0.2 mg of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch and 98.8 mg of lactose.
  • Appropriate coatings may be applied to increase palatability or delay absorption.
  • aqueous suspension can be prepared for oral administration so that each 5 mL contain 25 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, U.S. P., and 0.025 mg of vanillin.
  • a parenteral composition suitable for administration by injection can be prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution is sterilized by commonly used techniques .
  • An aqueous solution is prepared such that each 1 illiliter contains 10 milligrams of active ingredient, 1.8 milligrams methylparaben, 0.2 milligram propylparaben and 10 milligrams methylcellulose.
  • the solution is dispensed into 1 milliliter vials.
  • a homogeneous mixture of the active ingredient in polysorbate 80 is prepared such that the final concentration of the active ingredient will be 10 milligrams per container and the final concentration of polysorbate 80 in the container will be 1% by weight.
  • the mixture is dispensed into each can, the valves are crimped onto the can and the required amount of dichlorotetrafluoroethane is added under pressure.
  • Form 1, Form 2, Form 3, Form 4, Form 5 therapeutic agent component (a) of this invention can independently be in any dosage form, such as those described above, and can also be administered in various combinations, as described above.
  • component (b) is to be understood to represent one or more agents as described previously.
  • each agent of component (b) may also be treated the same or independently.
  • Components (a) and (b) of the present invention may be formulated together, in a single dosage unit (that is, combined together in one capsule, tablet, powder, or liquid, etc.) as a combination product.
  • component (a) and (b) are not formulated together in a single dosage unit, the component (a) may be administered at the same time as component (b) or in any order; for example component (a) of this invention may be administered first, followed by administration of component (b) , or they may be administered in the reverse order. If component (b) contains more that one agent, e.g., one RT inhibitor and one protease inhibitor, these agents may be administered together or in any order .
  • the administration of component (a) and (b) occurs less than about one hour apart.
  • the route of administration of component (a) and (b) is oral.
  • oral agent oral inhibitor, oral compound, or the like, as used herein, denote compounds which may be orally administered.
  • component (a) and component (b) both be administered by the same route (that is, for example, both orally) or dosage form, if desired, they may each be administered by different routes (that is, for example, one component of the combination product may be administered orally, and another component may be administered intravenously) or dosage forms.
  • the dosage of the combination therapy of the invention may vary depending upon various factors such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration, the age, health and weight of the recipient, the nature and extent of the symptoms, the kind of concurrent treatment, the frequency of treatment, and the effect desired, as described above .
  • the proper dosage of components (a) and (b) of the present invention will be readily ascertainable by a medical practitioner skilled in the art, based upon the present disclosure.
  • typically a daily dosage may be about 100 milligrams to about 1.5 grams of each component. If component (b) represents more than one compound, then typically a daily dosage may be about 100 milligrams to about 1.5 grams of each agent of component (b) .
  • the dosage amount of each component may be reduced by about 70-80% relative to the usual dosage of the component when it is administered alone as a single agent for the treatment of HIV infection, in view of the synergistic effect of the combination .
  • the combination products of this invention may be formulated such that, although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized. In order to minimize contact, for example, where the product is orally administered, one active ingredient may be enteric coated.
  • enteric coating one of the active ingredients it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines .
  • Another embodiment of this invention where oral administration is desired provides for a combination product wherein one of the active ingredients is coated with a sustained-release material which effects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients.
  • the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine.
  • Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a low- viscosity grade of hydroxypropyl methylcellulose or other appropriate materials as known in the art, in order to further separate the active components.
  • the polymer coating serves to form an additional barrier to interaction with the other component.
  • contact may also be prevented between the individual agents of component (b) .
  • Dosage forms of the combination products of the present invention wherein one active ingredient is enteric coated can be in the form of tablets such that the enteric coated component and the other active ingredient are blended together and then compressed into a tablet or such that the enteric coated component is compressed into one tablet layer and the other active ingredient is compressed into an additional layer.
  • one or more placebo layers may be present such that the placebo layer is between the layers of active ingredients.
  • dosage forms of the present invention can be in the form of capsules wherein one active ingredient is compressed into a tablet or in the form of a plurality of microtablets, particles, granules or non-perils, which are then enteric coated. These enteric coated microtablets, particles, granules or non-perils are then placed into a capsule or compressed into a capsule along with a granulation of the other active ingredient.
  • kits useful for the treatment of HIV infection which comprise a therapeutically effective amount of a pharmaceutical composition comprising a compound of component (a) and one or more compounds of component (b) , in one or more sterile containers, are also within the ambit of the present invention. Sterilization of the container may be carried out using conventional sterilization methodology well known to those skilled in the art. Component (a) and component (b) may be in the same sterile container or in separate sterile containers.
  • kits may further include, if desired, one or more of various conventional pharmaceutical kit components, such as for example, one or more pharmaceutically acceptable carriers, additional vials for mixing the components, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, may also be included in the kit.
  • ANALYTICAL METHODS x-Ray Powder Diffraction x-Ray powder diffraction data of Efavirenz were obtained with a Philips Model 3720 automated powder diffractometer . Samples were run in a batch mode with a Model PW 1775 multi-position sample changer. The diffractometer was equipped with a variable slit ( ⁇ - compensating slit) , a scintillation counter and a graphite monochromator . The radiation was CuK ⁇ (40kV,
  • the thermal properties of Efavirenz were characterized with differential scanning calorimetry using a TA Instruments DSC 910, with data analysis via a TA Instruments Thermal Analyzer 2100. Samples were placed in sealed aluminum pans for analysis with an empty aluminum pan serving as the reference. Heating rates of 5 °C per minute or 10 °C per minute were employed over a temperature range of 25 °C to 200 °C. The instrument was calibrated with a indium standard.
  • Example 1 Preparation of N- (4-chlorophenyl) -2 , 2- dimethyl propanamide .
  • Example 2 Preparation of 4-Chloro-2-trifluoroacetyl- aniline, hydrochloride hydrate.
  • N- (4-Chlorophenyl) -2 , 2-dimethyl propanamide (36.7 kg, 173 mol) was charged to a solution of TMEDA (20.2 kg, 174 mol) in anhydrous t-butyl methyl ether (271.5 kg) and cooled to -20°C.
  • TMEDA 20.2 kg, 174 mol
  • t-butyl methyl ether 271.5 kg
  • To the cold slurry was added 2.7 N n- butyllithium in hexane (101.9 kg, 393 mol) while keeping the temperature below 5°C.
  • Example 3 Preparation of N- ( (4 ' -Methoxy) benzyl) -4- chloro-2-trifluoroacetylaniline .
  • hydrochloride hydrate (40.0 kg, 144 mol) in toluene (140 kg) and water (50 L) was added 30% NaOH (18 kg) to pH 7.0.
  • 4-methoxybenzyl alcohol (20 kg, 144 mol) and TsOH (1.0 kg, 5.3 mol) were added.
  • the solution was heated to reflux and the water/toluene azeotrope (30 L) distilled.
  • the hydrochloride salt was charged to toluene (392 kg) and water (42 kg) and treated with 30% NaOH (approximately 55 kg, 414 mol) to a pH greater than 12. After removal of the lower aqueous phase, the organic solution was partially concentrated by distilling 140 L of solvent to give a 20 wt% solution of the title compound in toluene. The calculated yield was 50 kg (75%) .
  • An analytical sample was obtained by concentrating the toluene solution of the title compound in vacuo then recrystallizing from heptane: mp 46-48°C.
  • Example 3b Preparation of cyclopropylacetylene .
  • a mixture of 5-chloro-l-pentyne (23.0 kg, 224 mol) and anhydrous THF (150 kg) is cooled to -20°C.
  • n-Hexyllithium (2.3 eq. ; 158 kg of 30 wt.%) in hexane is added into the mixture at such a rate as to not allow the temperature to go over 5°C (approximately 2 hours) .
  • the temperature must remain above -5°C to prevent an accumulation of the organolithium and a dangerously exothermic induction reaction.
  • the reaction is aged at - 5 to 0°C for 2 hours, until GC analysis indicates at least 99% conversion.
  • Toluene (35 to 40 kg) is then added and the reaction is concentrated under vacuum until the volume is reduced to -1/3 of original volume.
  • the mixture is heated (to -40 °C) over the course of the concentration to maintain a good rate of distillation.
  • the mixture is then cooled to 15 to -20°C and a solution of ammonium chloride (11 to 12 kg) in 50 to 60 L water is added at such a rate as to not allow the temperature to go above 10°C.
  • the reaction mixture is circulated through a tower containing 15 kg of 3A molecular sieves until the water content is -300 ppm or lower as determined by Karl Fisher analysis.
  • the dried organic solution is then distilled through a column packed with steel wool at atmospheric pressure, collecting cyclopropylacetylene as a solution in THF/toluene/hexane.
  • the calculated yield is 14.0 kg.
  • Tetracholorophydroquinone was removed by filtration and washed with a mixture of heptane (104.7 kg) and ethyl acetate (31 kg) .
  • the filtrate was partially concentrated by distillation of 260 L solvent, then diluted with heptane (177 kg) and cooled to -10 to -15°C.
  • the resulting slurry was filtered and the product washed with heptane (41 kg) and dried on the filter to less than 20 wt% heptane (by loss on drying) .
  • the yield calculated by HPLC, was 71 kg (80%) .
  • Example 7 Preparation of (S) -6-Chloro-4- (cyclopropylethynyl) -l,4-dihydro-4- (trifluoromethyl) -2H-3 , 1- benzoxazine-2-one .
  • Examples 8-16 specifically teach the preparation of each of the forms of Efavirenz of the present invention, as well as methods to effectuate the interconversions of these forms (Scheme 5) .
  • the following examples are meant to be illustrative of the present invention, and not should not be taken as limiting the inventors scope.
  • Efavirenz 32 g, 0.1 mol was dissolved in 390 mL heptane and 20 mL of THF at 60 °C . The solution was allowed to cool down and at 45 °C it was seeded with 50 mg of DMP 266. After crystallization occurred, solvent was removed in vacuo and it was replaced with fresh heptane. The slurry was cooled to 0 °C and filtered. XRD indicated form IV. It was dried in a vacuum oven at 80 °C for 16 hours to yield 26 g of Form 1 (82% yield) .
  • Efavirenz (105 g, 0.33 mol) was slurried in 1.2 L of heptane and heated to reflux until dissolution. The solution was allowed to cool to 75 °C and it was filtered through #1 Whatman paper and cooled. A thin slurry crystallized, and a sample was filtered. x-Ray powder diffraction indicated Form 2. The slurry was stirred at room temperature for 24 hours and the resulting thick slurry was diluted with 200 mL of heptane, filtered and dried under vacuum at room temperature to yield 82.5 g (79%) . The solid was identified as Form 3 by X-ray powder diffraction. A 5 g sample was dried at 90 °C for 24 hours and the resulting solid was identified as form I by X-ray powder diffraction.
  • Efavirenz Form 1 (105 g, 0.33 mol) was slurried in 1.0 L of heptane at room temperature for seven days . A sample indicated no Form 1 present by XRD. The peaks obtained were the same as the one obtained starting from Form 2, although relative intensities were slightly different .
  • Efavirenz Form 2 (50 g, 0.16 mol) was slurried in 580 mL of heptanes. THF (7 mL, resulting in 1% THF in heptane) was added, heated to 40 °C and after 50 minutes a sample of the slurry was filtered and XRD (X-ray powder diffraction) still indicated Form 2. THF (28 mL, total 32 mL, resulting in 5 % THF in heptane) was added in four portions. After the addition of the last portion, the mixture was cooled to 28 °C, at which point a very thick slurry formed, confirmed to be Form 4 by XRD.
  • Efavirenz Form 1 (10 g, 0.03 mol) was slurried in 90 mL of heptane. The slurry was heated to 35 °C. THF was added in 2 mL portions . After the addition of a total of 6 mL (resulting solution -6% THF) , the slurry became very thick. XRD indicated Form 4.
  • EXAMPLE 15 Conversion of Form 2 to Form 1 by heating a slurry to 70 °C.
  • Efavirenz Form 2 (3 g, 0.01 mol) was slurried in heptane (42 mL) , heated to 70 °C and held for 2 hours. The slurry was cooled down to room temperature and a sample was filtered for XRD, indicating Form 1 only.
  • EXAMPLE 16 Conversion of Form 3 to Form 1 by heating a slurry to 70 °C.
  • Efavirenz Form 1 (3 g, 0.01 mol) was slurried in heptane (42 mL) for 48 hours. XRD indicated Form 3. The slurry was then heated to 70 °C, held for 2 hours, cooled to room temperature and a sample filtered for XRD, which indicated Form 1.
  • EXAMPLE 17 Direct crystallization of Form 5 Efavirenz Form 1 (approximately 70g) was slurried in
  • Efavirenz Form 1 (approximately 70 g) was slurried in 1.5 L of 1% v/v THF/heptane and warmed to 40°C. The solution was filtered warm (40°C) to remove any undissolved solids and the mother liquor was seeded with Form 5 at 40°C. As the solution cooled to room temperature, Form 5 crystallized. The solid was isolated by filtration at room temperature (9.43 g) .
  • Efavirenz Form 1 (approximately 70g) was slurried in 1 L of warm heptane and 10 mL of THF was added to adjust the solvent ratio to 1% v/v THF/heptane. The slurry was then heated to total dissolution at 85°C. As the solution cooled, it was seeded periodically with Form 5 until the seeds no longer dissolved (63°C) , then allowed to cool to 45°C and filtered. The solid isolated was Form 1. The solution was then allowed to cool to room temperature overnight and Form 5 crystals were then collected bv filtration (15.41 ⁇ ).
  • EXAMPLE 18 Conversion of Form 5 to Form 1.
  • Form 5 was dried at 95°C for 3 days in a vacuum oven with a nitrogen purge to give Form 1 which was identified by X-ray powder diffraction.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention concerne Efavirenz, le puissant inhibiteur de transcriptase inverse, produit sous forme cristalline. L'Efavirenz cristalline existe sous diverses formes physiques, désignées formes 1, 2, 3, 4 et 5. Il est caractérisé par la diffraction des rayons X à travers la poudre et par une calorimétrie de balayage différentielle. Les compositions pharmaceutiques le contenant ainsi que les procédés correspondants sont utiles pour le traitement du virus de l'immunodéficience humaine (VIH).
PCT/US1999/013199 1998-06-11 1999-06-10 Efavirenz sous forme cristalline WO1999064405A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
EP99927468A EP1086087A1 (fr) 1998-06-11 1999-06-10 Efavirenz sous forme cristalline
HU0103819A HUP0103819A3 (en) 1998-06-11 1999-06-10 Crystalline efavirenz pharmaceutical compositions containing it as active ingredient, and use of efavirenz for making medicament available for inhibitions of reverse transcriptase and for treating hiv infection
UA2000127048A UA74324C2 (uk) 1998-06-11 1999-06-10 Форми кристалічного ефавіренцу та способи лікування з їх допомогою
JP2000553414A JP2002517487A (ja) 1998-06-11 1999-06-10 結晶性エファビレンツ
SK1818-2000A SK18182000A3 (sk) 1998-06-11 1999-06-10 Kryštalický efavirenz
BR9911523-9A BR9911523A (pt) 1998-06-11 1999-06-10 Composto de efavirenz, composição farmacêutica, método para inibição da replicação por uma transcriptase reversa viralmente codificada e método para tratamento da infecção do hiv
IL139793A IL139793A (en) 1998-06-11 1999-06-10 Apavirench in a crystalline form
NZ507713A NZ507713A (en) 1998-06-11 1999-06-10 Crystalline efavirenz
AU44364/99A AU758114C (en) 1998-06-11 1999-06-10 Crystalline efavirenz
CA002333550A CA2333550A1 (fr) 1998-06-11 1999-06-10 Efavirenz sous forme cristalline
EEP200000743A EE05547B1 (et) 1998-06-11 1999-06-10 Kristalliline efavirens
PL345221A PL198504B1 (pl) 1998-06-11 1999-06-10 Postać 1, postać 2, postać 3, postać 4 i postać 5 krystalicznego (S)-6-chloro-4-cyklopropyloetynylo-4-trifluorometylo-1,4-dihydro-2H-3,1-benzoksazyn-2-onu i środek farmaceutycznyu
NO20006255A NO20006255L (no) 1998-06-11 2000-12-08 Krystallinsk efavirenz

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8898198P 1998-06-11 1998-06-11
US60/089,981 1998-06-11

Publications (1)

Publication Number Publication Date
WO1999064405A1 true WO1999064405A1 (fr) 1999-12-16

Family

ID=22214647

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/013199 WO1999064405A1 (fr) 1998-06-11 1999-06-10 Efavirenz sous forme cristalline

Country Status (21)

Country Link
EP (1) EP1086087A1 (fr)
JP (1) JP2002517487A (fr)
CN (1) CN1307568A (fr)
AR (3) AR018670A1 (fr)
AU (1) AU758114C (fr)
BR (1) BR9911523A (fr)
CA (1) CA2333550A1 (fr)
EE (1) EE05547B1 (fr)
HR (1) HRP990182A2 (fr)
HU (1) HUP0103819A3 (fr)
IL (1) IL139793A (fr)
MY (1) MY126450A (fr)
NO (1) NO20006255L (fr)
NZ (1) NZ507713A (fr)
PL (1) PL198504B1 (fr)
SG (3) SG134977A1 (fr)
SK (1) SK18182000A3 (fr)
TW (1) TWI235152B (fr)
UA (1) UA74324C2 (fr)
WO (1) WO1999064405A1 (fr)
ZA (1) ZA200006173B (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6639071B2 (en) 1997-02-05 2003-10-28 Merck & Co., Inc. Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
WO2008108630A1 (fr) * 2007-03-02 2008-09-12 Ultimorphix Technologies B.V. Formes polymorphes de l'efavirenz
WO2009011567A1 (fr) * 2007-07-16 2009-01-22 Ultimorphix Technologies B.V. Formes cristallines d'efavirenz
WO2011032634A1 (fr) 2009-09-16 2011-03-24 Archimica Gmbh Sels d'éfavirenz, leur procédé de préparation et de libération du sel
EP2471783A1 (fr) 2010-12-23 2012-07-04 Esteve Química, S.A. Nouvelle forme polymorphe de l'éfavirenz
US8222273B2 (en) 2008-02-04 2012-07-17 Pfizer Limited Polymorphic form of a [1,2,4]triazole[4,3-A] pyridine derivative inflammatory diseases
US8242267B2 (en) 2004-08-19 2012-08-14 Hetero Drugs Limited Polymorphs of efavirenz
US8383811B2 (en) 2008-12-22 2013-02-26 Hetero Research Foundation Process for preparing efavirenz polymorph
CN103508973A (zh) * 2012-06-25 2014-01-15 上海迪赛诺药业有限公司 制备依非韦伦i型结晶的方法
WO2014114971A1 (fr) * 2013-01-23 2014-07-31 Alienor Farma Dosage accru d'éfavirenz pour le traitement du cancer

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060587A1 (es) * 2004-09-02 2006-07-09 Bristol Myers Squibb Co Sintesis de (s)-6-cloro-4-ciclopropiletinil-4-trifluorometil-1,4-dihidro-2h-3,1-benzoxazin-2-ona
CN102924398B (zh) * 2012-11-22 2015-11-18 安徽贝克生物制药有限公司 用于除去依非韦伦对应异构体的方法
CN105037175B (zh) * 2014-07-18 2017-02-22 盐城迪赛诺制药有限公司 一种用于提高依非韦伦中间体光学纯度的方法
CN105001101B (zh) * 2015-05-28 2017-11-28 乐平市瑞盛制药有限公司 一种4‑氯‑2‑三氟乙酰基苯胺水合物盐酸盐的合成方法
CN108947855B (zh) * 2018-08-10 2021-10-22 江苏沙星化工有限公司 一种依非韦伦关键中间体的合成方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0582455A1 (fr) * 1992-08-07 1994-02-09 Merck & Co. Inc. Benzoxazinones utilisées comme inhibiteurs de transcriptase inverse de HIV
WO1995020389A1 (fr) * 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones en tant qu'inhibiteurs de transcriptase inverse du vih
WO1996037457A1 (fr) * 1995-05-25 1996-11-28 Merck & Co., Inc. Synthese asymetrique de (-) 6-chloro-4-cyclopropyle-ethynyle-4-trifluoromethyle-1,4-dihydro-2h-3,1-benzoxazin-2-one
WO1998004535A1 (fr) * 1996-07-26 1998-02-05 Du Pont Pharmaceuticals Company Synthese pratique de benzoxazinones utiles comme inhibiteurs de la transcriptase inverse du vih
WO1998014436A1 (fr) * 1996-10-02 1998-04-09 Dupont Pharmaceuticals Company 4,4-disubstitue-1,4-dihydro-2h-3,1-benzoxazine-2-ones utiles en tant qu'inhibiteurs de transcriptase inverse du vih et intermediaires et procedes de fabrication correspondants

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69841972D1 (de) * 1997-02-05 2010-12-09 Merck Sharp & Dohme Verfahren zur kristallisation eines reverstranskriptase-inhibitors, bei welchem ein anti-lösungsmittel benutzt wird

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0582455A1 (fr) * 1992-08-07 1994-02-09 Merck & Co. Inc. Benzoxazinones utilisées comme inhibiteurs de transcriptase inverse de HIV
WO1995020389A1 (fr) * 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones en tant qu'inhibiteurs de transcriptase inverse du vih
WO1996037457A1 (fr) * 1995-05-25 1996-11-28 Merck & Co., Inc. Synthese asymetrique de (-) 6-chloro-4-cyclopropyle-ethynyle-4-trifluoromethyle-1,4-dihydro-2h-3,1-benzoxazin-2-one
WO1998004535A1 (fr) * 1996-07-26 1998-02-05 Du Pont Pharmaceuticals Company Synthese pratique de benzoxazinones utiles comme inhibiteurs de la transcriptase inverse du vih
WO1998014436A1 (fr) * 1996-10-02 1998-04-09 Dupont Pharmaceuticals Company 4,4-disubstitue-1,4-dihydro-2h-3,1-benzoxazine-2-ones utiles en tant qu'inhibiteurs de transcriptase inverse du vih et intermediaires et procedes de fabrication correspondants

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939964B2 (en) 1997-02-05 2005-09-06 Merck & Co., Inc. Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
US6639071B2 (en) 1997-02-05 2003-10-28 Merck & Co., Inc. Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
US8242267B2 (en) 2004-08-19 2012-08-14 Hetero Drugs Limited Polymorphs of efavirenz
US8466279B2 (en) 2004-08-19 2013-06-18 Hetero Drugs Limited Polymorphs of efavirenz
WO2008108630A1 (fr) * 2007-03-02 2008-09-12 Ultimorphix Technologies B.V. Formes polymorphes de l'efavirenz
WO2009011567A1 (fr) * 2007-07-16 2009-01-22 Ultimorphix Technologies B.V. Formes cristallines d'efavirenz
US8222273B2 (en) 2008-02-04 2012-07-17 Pfizer Limited Polymorphic form of a [1,2,4]triazole[4,3-A] pyridine derivative inflammatory diseases
US8383811B2 (en) 2008-12-22 2013-02-26 Hetero Research Foundation Process for preparing efavirenz polymorph
WO2011032634A1 (fr) 2009-09-16 2011-03-24 Archimica Gmbh Sels d'éfavirenz, leur procédé de préparation et de libération du sel
DE102009041443A1 (de) 2009-09-16 2011-03-31 Archimica Gmbh Salze des 6-Chlor-4-(cyclopropylethinyl)-1,4-dihydro-4-(trifluormethyl)-2H-3,1-benzoxazin-2-ons und deren Synthese, Aufreinigung und Anwendung als Vorstufen für Efavirenz
EP2471783A1 (fr) 2010-12-23 2012-07-04 Esteve Química, S.A. Nouvelle forme polymorphe de l'éfavirenz
CN103508973A (zh) * 2012-06-25 2014-01-15 上海迪赛诺药业有限公司 制备依非韦伦i型结晶的方法
CN103508973B (zh) * 2012-06-25 2016-04-27 上海迪赛诺药业有限公司 制备依非韦伦i型结晶的方法
WO2014114971A1 (fr) * 2013-01-23 2014-07-31 Alienor Farma Dosage accru d'éfavirenz pour le traitement du cancer
US9468646B2 (en) 2013-01-23 2016-10-18 Alienor Farma Increased dosage of efavirenz for the treatment of cancer
AU2013375157B2 (en) * 2013-01-23 2018-07-12 Alienor Farma Increased dosage of Efavirenz for the treatment of cancer

Also Published As

Publication number Publication date
NO20006255D0 (no) 2000-12-08
SG134977A1 (en) 2007-09-28
EP1086087A1 (fr) 2001-03-28
IL139793A0 (en) 2002-02-10
AU758114C (en) 2003-10-30
EE200000743A (et) 2002-10-15
UA74324C2 (uk) 2005-12-15
AR077407A2 (es) 2011-08-24
JP2002517487A (ja) 2002-06-18
CN1307568A (zh) 2001-08-08
AR077469A2 (es) 2011-08-31
AU758114B2 (en) 2003-03-13
IL139793A (en) 2006-10-31
PL345221A1 (en) 2001-12-03
BR9911523A (pt) 2001-09-18
TWI235152B (en) 2005-07-01
HUP0103819A2 (hu) 2002-02-28
NO20006255L (no) 2001-02-12
AR018670A1 (es) 2001-11-28
SG111981A1 (en) 2005-06-29
NZ507713A (en) 2003-08-29
HRP990182A2 (en) 2000-02-29
ZA200006173B (en) 2001-10-31
SK18182000A3 (sk) 2001-08-06
CA2333550A1 (fr) 1999-12-16
SG111980A1 (en) 2005-06-29
EE05547B1 (et) 2012-06-15
AU4436499A (en) 1999-12-30
PL198504B1 (pl) 2008-06-30
MY126450A (en) 2006-10-31
HUP0103819A3 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
KR100612795B1 (ko) 결정성 에파비렌즈
AU758114C (en) Crystalline efavirenz
AU734928B2 (en) 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
CA2427227C (fr) Compose de lactam
EA004146B1 (ru) Сульфонамиды и их производные, модулирующие активность эндотелина
JP2001505873A (ja) Ｈｉｖ逆転写酵素阻害剤として有用な４，４―二置換―１，４―ジヒドロ―２ｈ―３，１―ベンゾオキサジン―２―オン類、およびそれらを製造するための中間体および方法
JPH08325263A (ja) 新規２−アミノ−３−フェニルプロピオン酸誘導体
US6423718B1 (en) 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
US6673372B1 (en) Crystalline Efavirenz
US6225317B1 (en) Crystalline (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1H)-quinazolinone
EP0848957A1 (fr) INHIBITEUR DE SOLUBILISATION DE LIGAND Fas
EP1542965A1 (fr) Formes de bicalutamide
MXPA00012228A (en) Crystalline efavirenz
CZ20004417A3 (cs) Krystalický Efavirenz
ZA200406027B (en) Novel amino acid derivatives method for productionthereof and pharmaceutical compositions comprisin g said derivative
US20020022742A1 (en) Salt forms of an HIV protease inhibitor
JPH09509158A (ja) エンケファリナーゼ及びａｃｅの阻害剤として有用な、新規なメルカプトアセチルアミドジスルフィド誘導体類
US20020022659A1 (en) Crystalline and salt forms of an HIV protease inhibitor
JPH11500754A (ja) 新規化合物および多発性硬化症の処置法
CA3225801A1 (fr) Synthese d'amides tricycliques substitues et analogues de ceux-ci
MXPA99008909A (en) 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitors
AU7371301A (en) 4,4-disubstituted-3,4-dihydro-2-)1H)- quinazolinones useful as HIV reverse transcriptase inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200100034

Country of ref document: VN

Ref document number: 99807219.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN CZ EE HU IL IN JP KR LT LV MX NO NZ PL RO SG SI SK UA VN ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 44364/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 507713

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2000/00553/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2000/06173

Country of ref document: ZA

Ref document number: 200006173

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1999927468

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 139793

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2333550

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PV2000-4417

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 18182000

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2000 553414

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/012228

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020007013999

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999927468

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2000-4417

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007013999

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 44364/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999927468

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020007013999

Country of ref document: KR

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载